The effectiveness of deep brain stimulation in dystonia: a patient-centered approach

Hendriekje Eggink MD, Rivka F Toonen, Jonathan C van Zijl MD, Martje E van Egmond MD, Anna L Bartels MD PhD, Rick Brandsma MD, M Fiorella Contarino MD PhD, Kathryn J Peall MD PhD, J Marc C van Dijk MD PhD, D L Marinus Oterdoom MD, Martijn Beudel MD PhD, Marina AJ Tijssen MD PhD

1 Expertise Center Movement Disorders Groningen, Department of Neurology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
2 Department of rehabilitation, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands
3 Ommelander Ziekenhuis Groningen, Department of Neurology, Delfzijl and Winschoten, the Netherlands
4 Haga Teaching Hospital, Department of Neurology, The Hague, The Netherlands
5 Leiden University Medical Center, Department of Neurology, Leiden, The Netherlands
6 Neuroscience and Mental Health Research Institute, Division of Psychological Medicine and Clinical Neuroscience, Cardiff University, Cardiff, United Kingdom
7 Department of neurosurgery, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands

Key words: Deep brain stimulation; dystonia; goal; patient-centered outcomes; daily functioning

Word count manuscript: 1267 words
Word count abstract: 150 words
Reference count: 8
Table and figure count: 2
Running title: Patient-centered approach to DBS in dystonia
Corresponding author: Hendriekje Eggink, MD PhD, Department of Neurology, HPC AB51, PO Box 30.001, 9700 RB Groningen, Groningen, the Netherlands, Telephone: +31-50-3612400, Fax: +31-50-3611707, Email: h.eggink@umcg.nl
HIGHLIGHTS

- Functional priorities in life of dystonia patients and their caregivers vary greatly
- The effect of DBS on functional priorities did not correlate with motor outcome
- Half of the motor ‘non-responder’ patients reported important changes in their priorities
- The effect of DBS in dystonia should not be measured by motor outcome alone
ABSTRACT

Background: To systematically evaluate the effectiveness of deep brain stimulation of the globus pallidus internus (GPi-DBS) in dystonia on pre-operatively set functional priorities in daily living.

Methods: Fifteen pediatric and adult dystonia patients (8 male; median age 32y, range 8-65) receiving GPi-DBS were recruited. All patients underwent a multidisciplinary evaluation before and 1-year post DBS implantation. The Canadian Occupational Performance Measure (COPM) first identified and then measured changes in functional priorities. The Burke-Fahn-Marsden Dystonia Rating Scale (BFMDRS) was used to evaluate dystonia severity.

Results: Priorities in daily functioning substantially varied between patients but showed significant improvements on performance and satisfaction after DBS. Clinically significant COPM-score improvements were present in 7/8 motor responders, but also in 4/7 motor non-responders.

Discussion: The use of a patient-oriented approach to measure GPi-DBS effectiveness in dystonia provides an unique insight in patients’ priorities and demonstrates that tangible improvements can be achieved irrespective of motor response.
INTRODUCTION

Dystonia is a movement disorder characterized by sustained or intermittent muscle contractions causing abnormal, often repetitive movements, abnormal posturing, or both. Dystonia comprises a heterogeneous patient population due to a broad spectrum of underlying acquired and inherited etiologies.[1] Over the past decades, deep brain stimulation of the globus pallidus internus (GPi-DBS) has emerged as a safe treatment option with a good response in non-lesional, mostly isolated forms of dystonia and a more variable response in combined forms of dystonia that are due to a static lesion or neurodegenerative process.[2] The application of this elective neurosurgical procedure therefore frequently gives rise to discussion, especially in secondary dystonia patients.

The effect of GPi-DBS has been predominantly measured with objective standardized dystonia rating scales. However, the variability of dystonic symptoms within days, or even hours or minutes, makes it difficult to reliably capture overall dystonia severity in just one evaluation. Furthermore, it is unclear how dystonia severity reflects disease burden and there is only weak evidence that a reduction in symptoms in isolated forms of dystonia may correlate with meaningful improvements in functioning.[3,4]

In line with the World Health Organization guidelines advocating patient-centered outcome measures,[5] we aimed to systematically evaluate the effect of DBS in terms of individualized functional priorities set by the patient and/or their caregivers.

METHODS

Patients

We prospectively included fifteen consecutive dystonia patients that received GPi-DBS between January 2013 and July 2016. All patients were evaluated pre and 1-year post-
operatively screened by a multidisciplinary team. The local ethical committee classified the
study as care as usual.

**Outcome measures**

Priorities were identified by the Canadian Occupational Performance Measure (COPM). The
COPM is an individualized outcome measure to capture everyday problems that impact daily
functioning. Together with a trained occupational therapist, patients and/or caregivers
imaginary walked through a typical day in the patient’s life to identify priorities that they
would like to see improved by GPi-DBS. For the three most important priorities performance
(1-10) and satisfaction (1-10) were rated. Change between pre- and postoperative ratings was
used for further analyses. At the 1-year follow-up, patients and/or their caregivers were
blinded for their pre-operative ratings. A difference of two or more points was considered
clinically significant.[6]

Dystonia severity was assessed with the motor subscale of the Burke-Fahn-Marsden dystonia
rating scale (BFMDRS). Videos were blinded for operative status and rated by experienced
clinicians (ALB, RB, KJP, MFC) who were blinded to treatment state. Mean total scores
were calculated. In order to be able to compare the results in all patients (generalized and
focal/segmental) the relative change in BFMDRS (% of improvement) was used for further
analyses. In addition, patients were subdivided into motor ‘responders’ (>20% change in
BFMDRS score) and ‘non-responders’ (<20% change in BFMDRS score).[7] For absolute
scores, see supplementary table 1.

**Data-analysis**

Data-analysis was performed using Statistical Package for the Social Sciences (SPSS, version
23.0). Due to the heterogeneity of the sample, medians and interquartile ranges (IQR) were
used. Differences between pre- and postoperative scores were compared with the Wilcoxon
Signed Ranked Test for total group and the responders and non-responder subgroups. Correlations between the outcome measures were calculated with the Spearman’s $\rho$.

**RESULTS**

Baseline characteristics, etiology and pharmacological treatment of all 15 patients (8 male; median age 32y range 8-65; median disease duration 8y range 3-47) are shown in table 1.

**Individual priorities**

The 45 priorities (3 per patient) were categorized in self-care/activities of daily living (ADL) (n=10); comfort in sitting and sleep (n=9); communication (n=7); social/leisure activities (n=7); and mobility (n=12). Communication priorities involved the ability to use an electric communication device, sign language or normal social interaction without interference of dystonic posturing. Social activities included sports, interactive games or going out for dinner. Mobility comprised walking, cycling, driving a car or the use of public transport.

For each patient, priorities comprised at least two categories. There was a very strong correlation between performance and satisfaction scores ($\rho = 0.86$, $p<0.0001$) and both scores significantly improved after the application of DBS (Table 2). At patient level, a clinically significant change in satisfaction in two or three individual priorities was reported in 73% (11) of the patients. In 47% all three priorities were improved, in 27% two priorities were improved, in 13% one priority was improved and in 13% none of the priorities was improved.

**Dystonia severity**

BFMDRS scores improved with a median change of 30% (pre 46.8 IQR 17.0-66.0 vs post 35.4 IQR 11.3-53.0; $p=0.027$). Eight patients (53%) were classified as responders with a decrease in their BFMDRS of more than 20% and seven (47%) as non-responders.
The non-responders were two patients with cerebral palsy (case 8 and 14), one patient with a mitochondrial disorder (case 1), one patient with DYT-THAP1 (case 6) and three patients with segmental dystonia (case 3, 12 and 15).

**Priorities versus dystonia severity**

Change in dystonia severity did neither correlate with change in performance ($\rho = -0.15$, $p=0.601$) nor satisfaction score ($\rho = 0.17$, $p=0.557$).

Seven of the eight responders reported a clinically significant improvement in performance and satisfaction on at least two or three individual functional priorities. In the group of non-responders, despite the lower motor response, clinical significant improvement in at least two priorities was achieved in four of these patients for performance and three for satisfaction, with a statistically significant change in COPM score (Case 6, 12, 14 and 15, $p=0.017$).

**DISCUSSION**

This prospective case series aimed to systematically evaluate the effectiveness of GPi-DBS as measured with change in preoperatively set functional priorities. The priorities of the patients and their caregivers lay within the domains of ADL, seating and sleep, communication, social/leisure activities and mobility. A clinically significant motor response coincided with improvements in functional priorities in 7/8 patients. Interestingly, half of the motor ‘non-responder’ patients also showed a clinically significant change in two or three priorities. Our findings are in line with a previous study in childhood dystonia showing that DBS may lead to improvement of functional goals also in patients with only moderate to ‘insignificant’ motor response.[8]

In contrast to the vast majority of efficacy studies primarily focusing on motor response, we evaluated effect of GPi-DBS by looking at functional priorities. These priorities provide an
unique insight in what patients and their caregivers identify as most important aspects in daily living. Given the heterogeneous nature of dystonia, it is not surprising that needs varied greatly between patients. An additional advantage is that this method may facilitate recognition of patients that might be unsuitable for the procedure due to goals that are unrealistic or not likely to be achieved by Gpi-DBS. One might argue that with a goal-oriented approach changes are subjective to the patients’ perception of improvement rather than objective symptom reduction. In addition, a potential placebo effect cannot be excluded in the absence of a control group. However, we agree with Kubu and colleagues that the main goal of DBS is to improve quality of life as perceived by the patient more than by the clinician, and that the effect of an elective neurosurgical option as DBS should be measured accordingly. In the future, it would be useful to objectify the patient centered outcome. This can be done by transforming the patients’ priorities into a treatment goal and pre-operatively decide with the patient and caregivers when the goal is met, for instance by using the goal attainment scale.

The heterogeneous patient sample may be seen as a limitation, both in terms of age as well as etiology. On the other hand, it can be seen as an advantage for the generalizability of the study. We did not correct for changes in medication, which could account for some of the perceived improvements. We realize that our conclusions are bases on a small case series with a possibly limited power, but hope these results serve as a pilot study to trigger future studies focusing on the effectiveness of Gpi-DBS in dystonia. First to assess to what extent a good motor outcome corresponds with the perceived outcome on the patient’s priorities. This may not always be the case, as 1/8 motor responders did not reach a significant improvement on his priorities, and might provide clarity in the repeatedly reported discrepancy between motor outcome and patient reported outcome. A systematical use of patient centered
outcomes might shine a new light on the current opinion that Gpi-DBS is more effective in isolated than in combined forms of dystonia.

In conclusion, the effect of Gpi-DBS should be measured not by motor symptom reduction alone, as clinically significant improvements on individual predefined priorities can be achieved irrespective of motor response. In addition, a goal- or patient-oriented approach provides unique insights in the priorities in daily living of dystonia patients and their caregivers. This may not only be of added value for DBS candidates, but also for patients across the entire dystonia population.

**FINANCIAL DISCLOSURES**

**A. Funding:** This work was supported by the Phelps Stichting voor Spastici (grant number 2014036, 2014)

**B. Financial Disclosures:** H Eggink received a MD/PhD bursary from the University Medical Center Groningen and a Ter Meulen grant (KNAW), and travel grants from COST Dystonia Europe, the Dutch Child Neurology Association (NVKN) and the Movement Disorder Society (MDS). JC van Zijl received a MD/PhD bursary from the University Medical Center Groningen and a research support fund from the Dutch Parkinson Society. MF Contarino is on the advisory board of and an independent consultant for research and educational issues for Medtronic. She received speaking fees from Novartis Pharma BV (CME activity). Received a grant from the Stichting Parkinson Fonds. The DBS center of the Haga Teaching Hospital/LUMC received compensation for DBS training activities and an unrestricted educational grant from Medtronic. KJ Peall is an MRC Clinician-Scientist Fellow (MR/P008593/1). MA Tijssen is funded by STW Technology Society–NeuroSIPE, Netherlands Organization for Scientific Research–NWO Medium, Fonds NutsOhra, Prinses Beatrix Fonds, Gossweiler Foundation, Phelps Stichting, Stichting wetenschapsfonds
dystonie vereniging, and educational grants from Ipsen, Allergan, Merz, Actelion, and Medtronic.

**C. Conflict of interest:** All other authors report no disclosures or conflict of interest.

**REFERENCES**


<table>
<thead>
<tr>
<th>Pt</th>
<th>Gender / age (yr)</th>
<th>Body distribution</th>
<th>Isolated or combined</th>
<th>Etiology</th>
<th>Pre-operative medical treatment</th>
<th>Post-operative medical treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>M/8</td>
<td>Generalized</td>
<td>Combined (spasticity)</td>
<td>Mitochondrional disorder</td>
<td>Gabapentin 100mg; intrathecal baclofen 3ug/hr</td>
<td>Unchanged</td>
</tr>
<tr>
<td>2</td>
<td>M/8</td>
<td>Generalized</td>
<td>Isolated</td>
<td>Idiopathic</td>
<td>THP 20mg</td>
<td>No</td>
</tr>
<tr>
<td>3</td>
<td>M/18</td>
<td>Segmental</td>
<td>Isolated</td>
<td>Idiopathic</td>
<td>THP 24mg; BTX</td>
<td>THP 24mg</td>
</tr>
<tr>
<td>4</td>
<td>F/22</td>
<td>Generalized</td>
<td>Isolated</td>
<td>ACTB mutation</td>
<td>THP 16mg; tramadol 50mg</td>
<td>THP 12mg; clonazepam 1.5mg; clozapine 18.75; BTX</td>
</tr>
<tr>
<td>5</td>
<td>F/32</td>
<td>Segmental</td>
<td>Isolated</td>
<td>Idiopathic</td>
<td>Ibuprofen; BTX</td>
<td>No</td>
</tr>
<tr>
<td>6</td>
<td>M/9</td>
<td>Generalized</td>
<td>Isolated</td>
<td>DYT-THAP1</td>
<td>THP 21mg; baclofen 12.5mg</td>
<td>THP 11mg</td>
</tr>
<tr>
<td>7</td>
<td>M/22</td>
<td>Segmental</td>
<td>Isolated</td>
<td>TTPA</td>
<td>Vitamin E</td>
<td>Unchanged</td>
</tr>
<tr>
<td>8</td>
<td>M/47</td>
<td>Generalized</td>
<td>Combined (spasticity)</td>
<td>Cerebral palsy</td>
<td>Antidepressants</td>
<td>Unchanged</td>
</tr>
<tr>
<td>9</td>
<td>M/53</td>
<td>Segmental</td>
<td>Isolated</td>
<td>Idiopathic</td>
<td>Clonazepam 0.5mg; BTX</td>
<td>BTX</td>
</tr>
<tr>
<td>10</td>
<td>F/65</td>
<td>Segmental</td>
<td>Combined (parkinsonism)</td>
<td>Idiopathic</td>
<td>Pramipexole; L-dopa; Diazepam 5mg; BTX</td>
<td>Pramipexole; L-Dopa</td>
</tr>
<tr>
<td>11</td>
<td>F/48</td>
<td>Generalized</td>
<td>Isolated</td>
<td>ACTB mutation</td>
<td>THP 12mg; clozapine 12.5mg; oxazepam 10mg; diclofenac; BTX antidepressant</td>
<td>THP 12mg; clozapine 12.5mg; antidepressant</td>
</tr>
<tr>
<td>12</td>
<td>F/63</td>
<td>Segmental</td>
<td>Isolated</td>
<td>Idiopathic</td>
<td>Clonazepam 2.5mg</td>
<td>Clonazepam 0.5mg</td>
</tr>
<tr>
<td>13</td>
<td>M/62</td>
<td>Segmental</td>
<td>Isolated</td>
<td>Idiopathic</td>
<td>BTX</td>
<td>Clonazepam 1.0mg; BTX</td>
</tr>
<tr>
<td>14</td>
<td>F/8</td>
<td>Generalized</td>
<td>Combined (spasticity)</td>
<td>Cerebral palsy</td>
<td>THP 1.5mg; baclofen 12mg; gabapentin 600mg; clonazepam 0.5mg</td>
<td>Unchanged</td>
</tr>
<tr>
<td>15</td>
<td>F/63</td>
<td>Segmental</td>
<td>Isolated</td>
<td>Idiopathic</td>
<td>No</td>
<td>No</td>
</tr>
</tbody>
</table>

ACTB: beta-actin gene; BTX: botulinum toxin injections; THP: trihexiphenidyl; TTPA α-tocopherol transfer protein – vitamin E.
Table 2: Pre- and postoperative COPM scores for all functional priorities and per subcategory

<table>
<thead>
<tr>
<th></th>
<th>COPM-Performance</th>
<th>COPM-Satisfaction</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Baseline</td>
<td>1 year</td>
</tr>
<tr>
<td>All priorities</td>
<td>3.0 (1.0-4.0)</td>
<td>7.0 (5.0-8.0)</td>
</tr>
<tr>
<td>Sitting and sleep</td>
<td>3.0 (2.0-4.0)</td>
<td>7.0 (5.5-8.0)</td>
</tr>
<tr>
<td>Personal/ADL</td>
<td>1.5 (1.0-4.3)</td>
<td>6.0 (2.5-7.3)</td>
</tr>
<tr>
<td>Communication</td>
<td>4.0 (3.0-4.0)</td>
<td>8.0 (6.0-10.0)</td>
</tr>
<tr>
<td>Social/leisure</td>
<td>3.0 (1.0-4.0)</td>
<td>7.0 (3.0-7.0)</td>
</tr>
<tr>
<td>Transfer</td>
<td>2.5 (1.3-4.8)</td>
<td>6.5 (5.3-7.0)</td>
</tr>
</tbody>
</table>

ADL activities of daily living; †Change or 2 point or more between baseline and 1-year post-operative score *p<0.0001